TP化疗方案联合特瑞普利单抗治疗晚期三阴性乳腺癌患者的临床效果  

Clinical effect of TP chemotherapy regimen combined with Toripalimab in the treatment of patients with advanced triple negative breast cancer

作　　者：覃海峰 QIN Haifeng(The Second Ward,Department of Oncology,People’s Hospital of Hechi,Guangxi Zhuang Autonomous Region,Hechi 547000,China)

机构地区：[1]广西壮族自治区河池市人民医院肿瘤科二病区,广西河池547000

出　　处：《妇儿健康导刊》2025年第3期107-111,共5页JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE

摘　　要：目的 探讨TP化疗方案联合特瑞普利单抗治疗晚期三阴性乳腺癌(TNBC)患者的临床效果。方法回顾性分析2019年1月至2021年12月河池市人民医院肿瘤科二病区收治的90例晚期TNBC患者的临床资料,根据不同的治疗方案分为对照组与观察组,每组各45例。对照组接受TP化疗,观察组在对照组基础上联合特瑞普利单抗治疗。比较两组临床疗效、生存期、肿瘤标志物水平、免疫功能及不良反应发生情况。结果 观察组客观缓解率高于对照组(P <0.05)。观察组中位无疾病生存期(9个月,95%CI:7.477~10.523)、中位总生存期(16个月,95%CI:12.423~19.577)均长于对照组(7个月,95%CI:5.917~8.083;12个月,95%CI:11.071~12.929),差异有统计学意义(P<0.05)。治疗后,观察组糖类抗原125、糖类抗原153、癌胚抗原水平均低于对照组(P <0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P <0.05)。两组不良反应总发生率比较,差异无统计学意义(P> 0.05)。结论 TP化疗方案联合特瑞普利单抗可有效提升晚期TNBC患者的客观缓解率,改善肿瘤标志物水平与免疫功能,具有临床应用前景。Objective To explore the clinical effect of TP chemotherapy regimen combined with Toripalimab in the treatment of patients with advanced triple negative breast cancer(TNBC).Methods A retrospective analysis of 90 patients with advanced TNBC admitted to the Second Ward,Department of Oncology,People’s Hospital of Hechi from January 2019 to December 2021 was performed.All the patients were divided into the control group and the observation group according to different treatment plans,with 45 cases in each group.The control group received TP chemotherapy,while the observation group received com bination therapy of T oripalimab on the bas is of the control group.T he clinical efficacy,survival time,tumor marker levels,immune function,and incidence of adverse reactions were compared between the two groups.Results The objective remission rate of the observation group was higher than that of the control group(P<0.05).The median disease-free-survival(9 months,95%CI:7.477-10.523)and median overall survival(16 months,95%CI:12.423-19.577)of the observation group were longer than those of the control group(7 months,95%CI:5.917-8.083,and 12 months,95%CI:11.071-12.929),with statistically significant differences(P<0.05).After treatment,the levels of carbohydrate antigen 125,carbohydrate antigen 153,and carcinoembryonic antigen in the observation group were lower than those in the control group (P < 0.05). After treatment, the observation group had higher levels of CD3^(+), CD4^(+), and CD4^(+)/CD8^(+), and lower CD8^(+) level than the control group, with statistically significance (P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion The combination of TP chemotherapy regimen and Toripalimab can effectively improve the objective remission rate of the patients with advanced TNBC, improve tumor marker levels and immune function, and has the prospect of clinical application.

关 键 词：TP化疗方案 特瑞普利单抗 三阴性乳腺癌 免疫功能 

分 类 号：R736.3[医药卫生—肿瘤]